Can we Boost Emicizumab Without Increasing Thrombosis Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn:
”Can we boost emicizumab without increasing thrombosis risk?
Emicizumab transformed hemophilia A care.
But breakthrough bleeding still happens, and treatment options remain imperfect.
A new RPTH study explores a provocative idea:
What if adding low-dose FIX plus FX together could safely enhance emicizumab-driven coagulation?
Here’s the key signal:
Combined FIX/FX supplementation restored coagulation potential to near-normal levels in vitro, in patient samples, and in hemophilia A mice.
Why this is biologically plausible:
- Emicizumab works by bridging FIXa and FX
- More FIX + FX to more ternary complex formation
- ~2× increase in FIX–emicizumab–FX complexes predicted
- Faster clot formation and reduced bleeding in vivo
- Thrombotic markers did not increase in animal models
Translation:
Rather than pushing bypassing agents harder, we may be able to optimize the emicizumab pathway itself.
Big questions for clinicians and researchers:
- Could FIX+FX become an alternative to rFVIIa for breakthrough bleeds?
- Could this strategy reduce treatment burden and dosing frequency?
- How do we balance enhanced hemostasis with real-world thrombosis risk?”
Title: Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
Authors: Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Find the Full Article on RPTH.”

Stay updated with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids